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Abstract
Bone metastases occur in ~70% of metastatic breast cancer patients often leading to skeletal 
injuries. Current treatments are mainly palliative and underscore the unmet clinical need for 
improved therapies. In this study, we provide preclinical evidence for an antimetastatic therapy 
based on targeting integrin β3 (β3) which is selectively induced on breast cancer cells in bone by 
the local bone microenvironment. In a preclinical model of breast cancer, β3 was strongly 
expressed on bone metastatic cancer cells but not primary mammary tumors or visceral 
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metastases. In tumor tissue from breast cancer patients, β3 was significantly elevated on bone 
metastases relative to primary tumors from the same patient (n=42). Mechanistic investigations 
revealed that TGF-β signaling through SMAD2/SMAD3 was necessary for breast cancer induction 
of β3 within the bone. Using a micelle-based nanoparticle therapy that recognizes integrin αvβ3 
(αvβ3-MPs of ~12.5nm), we demonstrated specific localization to breast cancer bone metastases 
in mice. Using this system for targeted delivery of the chemotherapeutic docetaxel, we showed 
that bone tumor burden could be reduced significantly with less bone destruction and less 
hepatotoxicity compared to equimolar doses of free docetaxel. Furthermore, mice treated with 
αvβ3-MP-docetaxel exhibited a significant decrease in bone-residing tumor cell proliferation 
compared to free docetaxel. Taken together, our results offer preclinical proof of concept for a 
method to enhance delivery of chemotherapeutics to breast cancer cells within the bone by 
exploiting their selective expression of integrin αvβ3 at that metastatic site.
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Introduction
Bone metastases occur in approximately 70% of metastatic breast cancer patients (1), often 
leading to the development of significant skeletal complications, such as pathological 
fracture, spinal cord compression, or bone pain (2). Current treatments – radiation, surgery, 
chemotherapy, and antiresorptive drugs – can improve quality of life but are rarely curative, 
with limited effect on overall survival (3-5). Treating breast cancer bone metastases has 
proven difficult due to frequent dissemination of metastases throughout the skeleton, a lack 
of tumor-specific targets expressed across breast cancer subtypes, and the chemo-protective 
nature of the bone microenvironment (2,6,7).
One approach to overcome these problems has been to enhance drug delivery to bone, most 
commonly by using bone matrix-targeted hydroxyapatite-avid bisphosphonates (8-10). 
Bisphosphonates are standard of care in patients with bone metastases or osteoporosis for 
their ability to inhibit osteoclast function and formation (1,2,10). While osteoclast inhibition 
can attenuate tumor-associated bone destruction with secondary effects on bone tumor 
growth, it does not improve overall survival in metastatic breast cancer patients (11,12). In 
line with this, bisphosphonate-targeted chemotherapy delivery can reduce mouse models of 
breast cancer-associated bone loss more effectively than free-drug chemotherapy (13,14). 
However, bisphosphonate-targeted drug delivery indiscriminately accumulates on all skeletal 
bone matrix and primarily targets osteoclasts and neighboring marrow cells near the bone 
matrix (8,15). To improve drug uptake by bone metastases, we sought to target tumor cells in 
the bone microenvironment more directly.
One targeting candidate of interest was the integrin αvβ3. Integrins are heterodimeric cell 
surface receptors, composed of an α and β subunit from a large family of subunits, that bind 
to components of the extracellular matrix or to other cells (16). Integrin are expressed in a 
cell-specific and context-dependent manner, and are critical to all aspects of cancer 
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progression and metastasis through effects on migration, invasion, and cell survival (16-18). 
Specifically, integrin αvβ3 is composed of the tightly regulated integrin subunit β3 and the 
more widely expressed αv subunit. Expression of αvβ3 on most cells in the body is 
typically low, but is elevated on several cancer types (17), as well as a variety of cell types 
that are important within the tumor microenvironment, such as osteoclasts (11,12), neo-
angiogenic endothelium (19), and tumor-promoting macrophages (20). The expression of 
αvβ3 on these cells led to the investigation of αvβ3 as a therapeutic target for cancer 
treatment (21). In several clinical trials, pharmacological inhibition with αvβ3 antagonists as 
a single-agent cancer therapy did not demonstrate a significant clinical effect (22,23). We, 
and others, have demonstrated that the inefficiency of αvβ3 inhibitors in advanced cancer 
may be due to the inherent complexities of integrin signaling and off-target effects of αvβ3 
antagonism (20,24).
Rather than aiming to antagonize αvβ3 function, we sought to utilize αvβ3 as a molecular 
target for enhancing drug delivery to cells of interest within the bone. Integrin β3 and αvβ3 
expression has been observed on human breast cancer bone metastases (25-27), and ectopic 
overexpression of tumoral β3 on breast cancer has been demonstrated to enhance tumor 
establishment in bone (26,28). However, for the purpose of targeting αvβ3, physiological 
expression on breast cancer during tumor growth and metastasis has not been defined. Here, 
we report that the bone microenvironment preferentially induces integrin β3 on breast cancer 
metastases, as compared to the primary tumor or visceral metastases, and we identify TGF-β 
to be responsible for this induction. Utilizing this information, we evaluated nanoparticle-
mediated drug delivery targeted against integrin αvβ3. We recently developed phospholipid/
polysorbate-80 micelle nanoparticles (MPs, ~12.5 nm) for their small size and unique 
mechanism of “contact-facilitated drug delivery” (29); in the present study, we demonstrate 
that integrin αvβ3-targeted micelle nanoparticles (αvβ3-MPs) carrying the 
chemotherapeutic docetaxel reduce bone metastases and tumor-associated bone destruction 
more effectively than free-docetaxel. Collectively, we demonstrate that αvβ3 is a tumor 
target on breast cancer bone metastases and provide support for safer, more effective 
therapies against this often incurable disease by targeting integrin αvβ3.
Materials and Methods
Animals
Animal studies were performed according to the guidelines established by the Washington 
University Institutional Animal Care and Use Committee (IACUC). PyMT-Bo1 tumor cells 
were implanted into female C57BL/6 mice, or 4T1 tumor cells were implanted into female 
BALB/c mice. All mice were obtained from The Jackson Laboratory, and injected at 6 to 7 
weeks of age. All rodents were housed according to the guidelines of the Division of 
Comparative Medicine, Washington University School of Medicine. In collaboration with 
Dr. Theresa Guise, histological bone sections from female athymic nude mice injected with 
MDA-MB-231 human breast cancer cells were obtained from an experiment previously 
described (30).
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Cell lines
The murine C57BL/6 PyMT-Bo1 luminal B breast cancer cell line (stably expressing GFP 
and firefly luciferase genes) was originally isolated from a transgenic MMTV-PyMT breast 
tumor, as previously validated and described (20). The murine BALB/c 4T1 triple-negative 
breast cancer cell line was purchased from ATCC, as previously described (31). Human 
MDA-MB-231 breast cancer cells (HTB-26) were purchased from ATCC (30). All cells 
were maintained at sub-confluence in DMEM with 10% FBS and 0.5% penicillin–
streptomycin, in a humidified chamber at standard culture conditions. Low-passage stocks 
were used and regularly tested for Mycoplasma and maintenance of growth characteristics.
Murine cancer models
To establish orthotopic mammary fat pad (MFP) tumors, 0.1×106 tumor cells in 50μL PBS 
were injected into MFP tissue of 7-week-old female mice. To establish experimental 
secondary metastases, 0.05×106 tumor cells in 50uL PBS were intracardiac injected into the 
left ventricular chamber of 6-week-old female, with one exception; in collaboration with Dr. 
Theresa Guise, human MDA-MB-231 tumor cells were intracardiac injected (0.1×106 tumor 
cells in 100μL PBS) into 4-week-old female athymic nude mice, as previously described 
(30).
Synthesis of αvβ3-targeted micelle nanoparticles
Phospholipid/polysorbate 80 micelle nanoparticles (MPs) were prepared as a microfluidized 
suspension of 20% (v/v), combining polysorbate tween 80 (Sigma Aldrich, Inc.) with a 2.0% 
(w/v) of a surfactant comixture, and 1.7% (w/v) glycerin in pH 6.5 carbonate buffer, as 
previously described (29). Optionally, the surfactant comixture included 2.28mol% of 
docetaxel-prodrug (DTX-PD), and/or 0.15mol% of αvβ3-targeted quinolone nonpeptide 
coupled to phosphatidylethanolamine-PEG2000, with the remaining mol% lecithin. 
Docetaxel was modified into an Sn2 lipase-labile phosphatidylcholine DTX-PD as 
previously described (32). For fluorescent labeling, rhodamine-conjugated to 
phosphatidylethanolamine (0.1 mol%) was incorporated into the lipid surfactant. The 
surfactant components for each formulation were combined with the polysorbate, buffer, and 
glycerin mixtures and were homogenized at 20,000 psi for 4 minutes at 4C with a 
microfluidics (M110s; Microfluidics, Inc). The nanoparticles were preserved under inert gas 
in sterile sealed vials until use. Dynamic light scattering showed a nominal particle size of 
12.5±0.8 nm, with polydispersities 0.290±0.03, and an average electrophoretic zeta potential 
of -3.82±1.23 mV.
The nanoparticle-targeting quinolone nonpeptide specific for integrin αvβ3 was originally 
developed by Bristol-Myers Squibb Medical Imaging (US patent 6,511,648 and related 
patents) and coupled to phosphatidylethanolamine-PEG2000, as previously described (29). 
The quinolone nonpeptide was initially characterized as the 111In-DOTA conjugate RP478 
and cyan 5.5 homologue TA145 (33). This αvβ3-targeting ligand is selective for cells 
expressing αvβ3 (IC50 = 12 nM), as compared to IC50>10 μM for ανβ5, α5β1, or αIIββ3 
(34). Furthermore, the affinity of the ανβ3-targeting ligand increases 15-fold for activated 
integrin αvβ3 receptor in the presence of Mn2+ (33). In vitro, pretreating human endothelial 
with the human-specific integrin αvβ3 antibody (LM609) competitively inhibited binding of 
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this αvβ3-targeting ligand (33). This αvβ3-targeted ligand has been applied to the surface of 
large, vascular-constrained perfluorocarbon nanoparticles (~250nm), which displayed a 
specific affinity for αvβ3-expressing angiogenic blood vessels and αvβ3-expressing 
melanoma cells, in contrast to nanoparticle controls (32,35,36). The in vivo specificity of 
this αvβ3-targeting ligand has been further demonstrated through competitive pretreatment 
with unlabeled αvβ3-targeting ligand, which inhibited αvβ3-targeted nanoparticle binding 
(35).
Bioluminescence imaging (BLI)
In vivo and ex vivo BLI was performed on IVIS50 (PerkinElmer, Waltham, MA) as 
previously described (20). Total photon flux (photons/sec) was measured from fixed regions 
of interest (ROIs) over entire mouse or manually around ex vivo organs using Living Image 
2.6, as indicated. Mice with outstanding chest BLI intensity indicative of a failed 
intracardiac injection or with ineffective D-luciferin administration were excluded from all 
analyses. Investigators were blinded to treatment groups during all BLI analyses.
Rhodamine-labeled MP colocalization with breast cancer bone metastases
Tumor-bearing mice day 8 post-intracardiac injected with PyMT-Bo1 cells, or age-matched 
tumor-free mice, were treated with a single dose of rhodamine-labeled MPs (either non-
targeted or αvβ3-targeted) at a nanoparticle dose of 2nmol/g mouse weight. Investigators 
were blinded to treatment groups during intravenous MP and αvβ3-MP injections. MPs 
were allowed to circulate for 3 hours in vivo, before sacrifice and tissue collection. Unbound 
MPs were cleared from circulation via cardiac perfusion with 30mL of PBS.
For fluorescent analysis of nanoparticle colocalization within bone, fresh-frozen long bones 
in optimum cutting temperature embedding medium (Tissue-Tek) were sectioned 5μm thick 
onto cryofilm tape (Section Lab Co., Ltd, Hiroshima, Japan) at the histology core of the 
Washington University Musculoskeletal Research Center. Cryofilm tape sections were fixed 
in -20°C acetone for 5 minutes and air-dried for 10 minutes. Slides were briefly rehydrated 
with PBS, and then mounted with ProLong Gold with DAPI (Invitrogen).
Fluorescent imaging and analysis
Fluorescent images were captured on a Photometrics CoolSNAP MYO camera connected to 
a Nikon Eclipse Ti-E microscope, acquired with the 4x Plan Fluor PhL DL objective through 
a TxRED HYQ filter cube and DAPI filter cube. The TxRED fluorescent channel was 
equally set using fluorescent look-up-table (LUT) to the same minimum and maximum 
values, gamma=1. Fluorescent colocalization analysis was performed using NIS-Elements 
AR (Nikon Canada, Inc., Richmond, BC, Canada). Bone metastatic region of interest (ROI) 
was drawn at the tumor/marrow boundary, as defined by DAPI visualization of nuclei 
density. Using the object count function in NIS-Elements AR, fluorescent nanoparticle 
colocalization was calculated via the ratio of rhodamine-positive pixel area by the total 
tumor ROI pixel area [(number of pixels of positively labeled objects within the fixed tumor 
area) / (total number of pixels within the fixed tumor area) × 100].
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Treatment of murine breast cancer metastases
Using the experimental metastasis model, PyMT-Bo1 metastases were established within 
female C57BL/6 mice. BLI analysis confirmed the establishment of bone metastases on day 
3 post-intracardiac injection, and metastatic-bearing mice were randomly sorted and 
treatment started. Docetaxel (LC Laboratories, Woburn, MA) was prepared at 10 mg/mL in a 
tween80/ethanol/saline (20:13:67, v/v/v) solution for drug solubility, and diluted to 0.5 
mg/mL DTX or 1.0 mg/mL in saline for intravenous administration. For nanoparticle 
treatment, mice received either a cumulative dose of 5.55 mg/kg docetaxel, an equimolar 
dose of nanoparticle-encapsulated docetaxel-prodrug (2.2 μmol/kg), or an equal amount of 
saline or cargo-free αvβ3-MP, fractionally administered intravenously every three days. A 
priori comparisons of interest were between saline-treated mice as compared to DTX or 
αvβ3-MP/DTX-PD, or between saline-treated mice compared to the nanoparticle control 
treatments.
In collaboration with Dr. Theresa Guise, histological bone sections were obtained from 
female athymic nude mice bearing MDA-MB-231 bone metastases, treated daily with the 
TGF-β Receptor I kinase inhibitor, 60 mg/kg/d SD-208 (Epichem Pty Ltd, Murdoch 
University, Australia) or vehicle (1% methylcellulose), from an experiment previously 
published (30).
Serum chemistry and hematologic analysis
Blood was collected by submandibular vein puncture into Microtainer EDTA tubes (BD 
Biosciences) for hematologic analysis (Hemavet 950 FS; Drew Scientific, Inc., Dallas, TX) 
or Microtainer serum separator tubes (BD Biosciences) for serum chemistry analysis on a 
Liasys 330 AMS Diagnostic liquid chemistry analyzer (Weston, FL). Investigators were 
blinded to treatment groups during analysis.
MTT assay
The MTT assay was performed as described previously (31). Signal intensity normalized to 
0% for the viability of cells at time of drug addition, and 100% for the viability of vehicle 
control treated cells at 72 hr.
Radiography
Osteolytic lesions were imaged by X-Ray imaging system (Faxitron, Buffalo Grove, IL), and 
lesion area within the tibiofemoral joint was quantified using ImageJ (NIH, Bethesda, 
Maryland).
Immunohistological staining
Freshly removed tissue was fixed in 10% neutral buffered formalin for 24 hours. Bone was 
decalcified in 14% EDTA for 10 days. Tissue was paraffin embedded and sectioned 5μm 
thick at the histology core of the Washington University Musculoskeletal Research Center. 
Standard tartrate-resistant acidic phosphatase (TRAP) staining or hematoxylin and eosin 
(H&E) staining was performed by the musculoskeletal histology core of the Washington 
University Musculoskeletal Research Center.
Ross et al. Page 6
Cancer Res. Author manuscript; available in PMC 2018 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
For immunohistochemistry, all slides were stained in parallel, using identical staining 
conditions. Paraffin tissue slides were prepared by immersing slides in xylene and 
rehydrating tissue in 100% ethanol, 95% ethanol, 70% ethanol, 50% ethanol, and deionized 
water washing steps. Slides were immersed in EDTA antigen retrieval buffer (1mM EDTA, 
0.05% Tween 20, PH 8.0) at 50 °C overnight. Slides were treated with dual endogenous 
enzyme block (Dako), TBS/0.1% Tween-20 (TBST) wash buffer, and 10 minutes of serum-
free protein block (Dako). Slides were stained with the following primary antibodies: anti-
integrin β3 antibody (D7X3P, 1:200, Cell Signaling), anti-integrin αv (ab179475, 1:500, 
Abcam), isotype control rabbit IgG (ab27472, Abcam) antibody, or biotinylated anti-PCNA 
antibody (PC10, 1:100, eBioscience). Following primary antibody incubation, slides were 
extensively washed in TBST. Either Anti-Rabbit EnVision+ System-HRP (Dako) or 
Vectastain Elite ABC HRP kit (Vector Laboratories, Burlingame, California) was used as the 
secondary antibody, followed by Liquid DAB+ (3,3’-Diaminobenzidine) Substrate system 
(Dako), according to the manufacturer’s protocol. Nuclear hematoxylin counterstain was 
applied, followed by dehydration through 70% ethanol, 95% ethanol, 100% ethanol, and 
xylene. Slides were mounted with Cytoseal XYL (Thermo Scientific).
Histological imaging and analysis
Histological slides were imaged on either an Olympus NanoZoomer 2.0-HT System or on a 
Zeiss AxioScan.Z1. In each experiment, post-image analysis was limited to changes in 
brightness or contrast, gamma = 1, which were applied equally to all images. Sections 
stained with integrin β3 or proliferating cell nuclear antigen (PCNA) were quantified using 
Visiopharm software (Hørsholm, Denmark), which allows for recognition and quantification 
of DAB-stained tissue areas. A supervised bayesian pixel classifier was used to classify an 
image based on three distinct categories: DAB staining, hematoxylin staining (nuclei), and 
unstained tissue and other background structures. Integrin β3 expression from each sample 
was calculated within 5 to 10 random high-powered fields (hpf) of 100-200 cells within the 
tumors. Values expressed as the percentage of integrin β3 expression (area of total DAB-
positive staining) divided by the tumor area in the hpf. PCNA proliferation index was 
quantified by calculating the number of PCNA-positive cells divided by the total number of 
cells within the entire bone metastatic region. ImageJ software (NIH, Bethesda, Maryland) 
was used to measure tumor area, and to quantitate osteoclasts (OCs) (defined as a TRAP 
positive, multinucleated cell on a bone surface) per millimeter of bone surface (mmB.S.) at 
the tumor/bone interface (N.OC/mmB.S.). Histological analysis of bone metastatic tumor 
burden (tumor area / total bone marrow area) was calculated by measuring the tumor area 
within the metaphysis of the tibiofemoral joint, divided by the total marrow area of the 
metaphysis.
Flow cytometry and fluorescence activated cell sorting (FACS)
In vitro tumor cells were lifted with 1x Versene (Invitrogen). Ex vivo tumor cells were 
collected from the MFP or the bone, and prepared into single-cell suspensions for flow 
cytometry analysis as previously described (20). Ex vivo cells were stained with PE-
conjugated anti-mouse integrin β3 (1:200, clone: 2C9.G2, BD Pharmingen), fixed and 
permeabilized using the Cytofix/Cytoperm kit (BD Biosciences) according to the 
manufacturer’s protocol, and then with AlexaFluor488-conjugated anti-human/mouse 
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cytokeratin 18 (1:100, clone LDK18, eBioscience). Data acquisition was performed on the 
LSRFortessa (BD Biosciences) and FlowJo software version 10.1 (Tree Star) was used for 
analysis, and fluorescent compensation using UltraComp eBeads (eBioscience) according to 
the manufacturer’s protocol. All flow cytometry data presented as median fluorescent 
intensity (MFI). Ex vivo flow cytometry analysis of bone samples with insufficient number 
of tumor cells (<500 events) were excluded.
For fluorescence activated cell sorting (FACS), in vitro tumor cells were lifted with 1x 
Versene (Invitrogen) and stained for surface expression of integrin β3 as described above. 
Tumor cells were sorted into two populations using a BD FACSAria-II cell sorter (BD 
Biosciences): integrin β3 negative (β3-) cells (based on the fluorescent intensity of unstained 
cells) and integrin β3-expressing (β3+) cells. In addition, control cells sorted without β3 
discrimination were also collected (β3-all). After sorting, each population was counted for 
live/dead cells, and 0.05×106 live tumor cells in 50uL PBS were intracardiac injected into 
the 6-week-old female mice.
Pharmacological inhibition of signaling pathways
Tumor cells were pretreated for 1 hour with pharmacological inhibitors: cells were 
pretreated for 1 hour with the following pharmacological inhibitors: TGFβ-receptor I kinase 
inhibitor, specific for the site necessary for SMAD2/SMAD3 phosphorylation (SMAD2/3i, 
SB431542, 20 μM, Sigma-Aldrich); p38 MAP kinase (MAPK) inhibitor (p38i, SB203580, 
20 μM, Cell Signaling); MEK1/2 (MAPK/ERK Kinase) inhibitor (MEK1/2i, U0126, 20 μM, 
Cell Signaling); c-Jun N-terminal kinase (JNK) inhibitor (JNKi, SP600125, 50 μM, Sigma-
Aldrich). After 1 hour of pretreatment, cells were treated with 2 ng/mL of murine TGF-β1 
(R&D systems) or vehicle treatment. Cells were all cultured in 0.1% DMSO.
Western blot analysis
Whole cell lysates from tumor cells were collected in RIPA buffer (Cell signaling) in the 
presence of Halt phosphatase inhibitor cocktail (Thermo Scientific) at 4°C. Protein samples 
were separated on 10% Mini-PROTEAN TGX polyacrylamide gels (Bio-Rad) and 
transferred onto an Immobilon-P polyvinylidene difluoride membrane (EMD Millipore). 
Membranes were incubated with phosphorylated-SMAD2/phosphorylated-SMAD3 
(pSMAD2/pSMAD3, D27F4), total SMAD2/SMAD3 (D7G7), integrin β3 (D7X3P), or β-
actin (13E5), followed by horseradish peroxidase-conjugated anti-rabbit secondary antibody 
(all from Cell Signaling). All antibodies were diluted and used according to the 
manufacturer’s protocol. Bands were developed by enhanced chemiluminescence.
Real-time quantitative PCR (qPCR) analysis
Total RNA from cells was isolated with the RNeasy Mini Plus kit (Qiagen). Complementary 
DNA was made using the SuperScript II first-strand synthesis system for qPCR (Invitrogen). 
qPCR was performed using SYBR Advantage mix (Bio-Rad) as previously described (20), 
with mouse-specific primers for mRNA genes of interest: Itgb1 forward: 5’-
GCAGGTGTCGTGTTTGTGAATGCT-3’, Itgb1 reverse: 5’-
ACAAGTTGGCCCTTGAAACTTGGG-3’, Itgb3 forward: 5’-
TTCAATGCCACCTGCCTCAACAAC-3’, Itgb3 reverse: 5’-
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ACGCACCTTGGCCTCGATACTAAA-3’, Itgb5 forward: 5’-
TGTTCAGCTACACAGAACTGCCCA-3’, Itgb5 reverse: 5’-
TTTGGAACTTGGCAAACTCTCGGC-3’, Itgb6 forward: 5’-
TCAAACCTCCTTCACTCCTGCCAT-3’, Itgb6 reverse: 5’-
TGAATCTGCTGGTTGCTCCAGACT-3’, Itgb8 forward: 5’-
CAACTGCATCCAGGAGCTGA-3’, Itgb8 reverse: 5’-
AACCAAGACGGAAGTCACGG-3’, Itga2 forward: 5’-
AGCCCGTGATCTTTCCTAAAC-3’, Itga2 reverse: 5’-
GCAGCCACAGAGTAACCTAAA-3’, Itga2b forward: 5’-
ACATTGAGGGCTTTGAGAGGCT-3’, Itga2b reverse: 5’-
TTGCCACAGGCAACATCACG-3’, Itga3 forward: 5’-GCGGAAGGACTGGGATTTAT-3’, 
Itga3 reverse: 5’-GATGATGTCCGTGGGATGTAG-3’, Itgav forward: 5’- 
AGAAGACGTTGGGCCTATTG-3’, Itgav reverse: 5’-
TGTAAGGCCACTGGAGATTTAG-3’, Gapdh forward: 5’-
AGGTCGGTGTGAACGGATTTG-3’, Gapdh reverse: 5’-
TGTAGACCATGTAGTTGAGGTCA-3’. Target gene expression was normalized against the 
housekeeping gene GAPDH (Gapdh), and data were analyzed using the ΔΔCt method.
Panel of cytokines and growth factors
Tumor cells were cultured for 24 hours with the following murine factors: 2 ng/mL TGF-β1 
(R&D Systems), 2 ng/mL TGF-β2 (R&D Systems), 50 ng/mL Sonic Hedgehog (Shh) 
(PeproTech, #315-22), 50 ng/mL WNT-3A (PeproTech, #315-20), 100 ng/mL Insulin-Like 
Growth Factor 1 (IGF-1) (PeproTech, #250-19), 50 ng/mL Epidermal growth factor (EGF) 
(PeproTech, #315-09), 50 ng/mL Fibroblast Growth Factor 2 (FGF2 or bFGF) (PeproTech, 
#450-33), 100 ng/mL Osteopontin (OPN) (Leinco, #O121), 10 ng/mL Interleukin 4 (IL-4) 
(R&D systems), 200 ng/mL Stromal Cell-derived Factor 1α (SDF-1α or CXCL12) 
(Biolegend), 10 ng/mL Interleukin 6 (IL-6) (R&D systems).
Patient breast cancer and matching bone metastatic biopsies
Matching primary breast and bone metastatic biopsies were both taken at the time of 
metastatic diagnosis, from patients without detectable bone metastases at diagnosis but 
detectable bone metastases at least 6 months after diagnosis. Data was obtained in 
accordance with the guidelines established by the Washington University Institutional 
Review Board (IRB #201102394) and WAIVER of Elements of Consent per 45 CFR 46.116 
(d). All patient information was de-identified prior to sharing with investigators. All of the 
human research activities and all activities of the IRBs designated in the Washington 
University (WU) Federal Wide Assurance (FWA), regardless of sponsorship, are guided by 
the ethical principles in “The Belmont Report: Ethical Principles and Guidelines for the 
Protection of Human Subjects Research of the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research.”
Tissue samples all displayed detectable tumor cells, as previously determined by 
examination of cellular morphology by a board-certified pathologist. Immunohistochemistry 
for integrin β3 was performed as described in the previous section. Tumor-associated β3 
expression was semi-quantitatively scored in a blinded manner, in which the scorer did not 
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have access to disease classification or clinical annotation, using the histoscore (H-score) 
system: H-score = Σ (i × %), where ‘i’ is the staining intensity (0 to 3 scale), and ‘%’ is the 
percentage of tumor cells stained at each intensity, ranging 0% to 100%. We observed an 
expression pattern of tumoral β3 consistent with a previous literature description of β3 
expression in human breast cancer: primarily localized along the cell plasma membrane at 
sites of tumor-tumor and tumor-stroma contact (37). In addition to the β3 expression on 
bone metastases, we also observed β3 staining on some host cells within the primary and 
bone tumor microenvironments, including tumor-infiltrating immune cells (β3 expression 
colocalized with CD68-stained cells, predominately expressed on monocytes and 
macrophages), tumor-associated blood vessels, and osteoclasts, consistent with previous 
observations (11,12,19,20).
Breast cancer subtyping was based on ER,PR,HER2 status, where luminal A was ER+,PR
±,HER2- (n=18), luminal B was ER+,PR±,HER2+ (n=7), HER2-enriched was 
ER-,PR-,HER2+ (n=2), and triple-negative was ER-,PR-,HER2- (n=7). Eight breast cancer 
carcinomas had incomplete genetic subtyping and were excluded from molecular subtype 
analysis.
Statistical analysis
All data shown as mean with error bars representing SEM. All sample sizes reported in the 
study are the minimum number of samples. For animal studies, sample sizes were estimated 
according to our previous experience. Statistical differences were analyzed using either a 
two-tailed t-test, ANOVA with Tukey’s test for a posteriori (post-hoc) multiple comparisons, 
or a two-tailed unpaired t-test with Bonferroni correction for a priori comparisons between a 
control group and experimental treatment groups of interest. Assumptions for ANOVA and 
t-test (independent samples, approximately normal distributions) for samples n>5 were 
sufficiently met, or used if a random sample of n≤5 were selected from an approximately 
normally distributed population. Non-normally distributed data was analyzed using a two-
tailed Mann–Whitney U-test or a two-tailed Wilcoxon signed-rank test for matched-pairs. 
All tests were considered significant at P<0.05, or in case of k comparisons, P<0.05/k. Data 
analyses were complete using Prism 6 (GraphPad Software).
Results
Breast cancer cells overexpress integrin β3 within the bone microenvironment
To determine the potential of targeting αvβ3 at different metastatic sites, we evaluated breast 
cancer expression of integrin αv or β3 at the primary site as compared to secondary 
metastases. Using the murine breast cancer cell line PyMT-Bo1 that models the luminal B 
subtype, primary MFP tumors were established by orthotopic injection, or metastases within 
the bone and visceral organs were established by intracardiac injection, into separate cohorts 
of mice. Tumors were removed 12 days post-injection and stained for integrin β3 or integrin 
αv expression using immunohistochemistry. Bone metastases expressed elevated levels of 
β3, as compared to MFP tumors or visceral metastases within the lung or kidney (Fig. 1A 
and Supplemental Fig. S1A). Unlike the selective upregulation of integrin β3 on bone 
metastases, we observed expression of integrin αv across all primary and metastatic tumors 
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(Supplemental Fig. S1B). To determine whether the observed β3 expression was tumor-cell 
specific, we used flow cytometry to quantify cell surface β3 expression. Using PyMT-Bo1 
cells or murine 4T1 triple-negative breast cancer cells, MFP tumors or bone metastases were 
established by orthotopic injection or intracardiac injection, respectively. Isolated tumor 
cells were identified based on cytokeratin 18 (CK18+) expression (Supplemental Fig. S1C). 
In both cell lines, tumor cells from bone metastases expressed significantly elevated β3 
levels, as compared to MFP tumor cells (Fig. 1B,C).
To assess the translational implications of this observation, we examined β3 expression on 
biopsies from 42 breast cancer patients, comparing patient-matched primary tumors to bone 
metastases. Immunohistochemistry for β3 was semi-quantitatively scored based on the 
extent and intensity of tumor-associated β3 expression. Across nearly all patients, human 
bone metastases expressed significantly higher levels of tumor-associated β3, as compared 
to the matching primary tumor (Fig. 2A and Supplemental Fig. S1D). Furthermore, this 
elevated expression of bone metastatic β3 was observed across all breast cancer patient 
subtypes: luminal A, luminal B, HER2-enriched, and triple-negative (Fig. 2B).
Tumoral β3 is induced in the bone microenvironment and mediated by TGF-β signaling
We next asked whether bone metastases express elevated β3 due to preferential seeding and 
colonization of a β3hi tumor cell subpopulation in the bone. Using fluorescence-activated 
cell sorting (FACS), PyMT-Bo1 cells were sorted into three different subpopulations based 
on surface β3 expression: β3-negative cells (β3-), β3-expressing cells (β3+), and control 
cells sorted without β3 discrimination (β3-all). These PyMT-Bo1 subpopulations were 
collected and injected intracardially into separate groups of mice, which all developed bone 
metastases (Fig. 3A). Flow cytometry revealed that regardless of initial β3 status, each FACS 
subpopulation developed into bone metastases that strongly expressed tumoral β3 (Fig. 3B). 
This result demonstrates that elevated expression of bone metastatic β3 is not due to 
preferential seeding of β3hi tumor cells to the bone, and suggests that tumoral β3 is induced 
in the bone microenvironment.
To ascertain pathways that might be responsible for this induction, we evaluated a panel of 
cytokines and growth factors present in the bone microenvironment for their effect on β3 
expression. Of the tested factors, only members of the TGF-β family upregulated integrin β3 
expression, observed in both PyMT-Bo1 and 4T1 cells (Fig. 3C,D). To assess the specificity 
of TGF-β-mediated upregulation of integrin β3 as compared to other related integrin 
subunits, we evaluated how TGF-β alters expression of integrin αv, as well as a subfamily of 
β-integrin subunits that can also heterodimerize with integrin αv (integrin subunits β1, β5, 
β6 and β8). In addition, we evaluated integrin αIIb (glycoprotein-IIb), which is largely 
restricted to platelets and megakaryocyte-lineage cells but can also heterodimerize with 
integrin β3 (16), and integrin α2, which facilitates adhesion to type I collagen and is 
upregulated on prostate cancer lines in response to TGF-β (38).
Collectively, we evaluated gene expression of integrin subunits β1, β3, β5, β6, β8, αv, αIIb, 
and α2 on PyMT-Bo1 and 4T1 cells, following 24 hours of in vitro TGF-β stimulation. 
Integrin β3 was the most upregulated subunit in both PyMT-Bo1 and 4T1 cells 
(Supplemental Figure S2A,B). In PyMT-Bo1 cells, integrin α2 was the next most 
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upregulated subunit, though 5-fold less than the level of β3 induction (Supplemental Figure 
S2A). In 4T1 cells, β5 and α2 were the next most upregulated subunits, though 4-fold less 
than the level of β3 induction (Supplemental Figure S2A). TGF-β-mediated changes in αv, 
αIIb, and the other β-integrin subunits were either unchanged, reduced, or displayed a less-
than 2-fold upregulation (Supplemental Figure S2A,B). These results provide support for 
TGF-β as a potent inducer of integrin β3 as compared to these other integrin subunits.
TGF-β signals through TGF-β Receptor 1 (TGFβR1), which canonical phosphorylates the 
transcription factors SMAD2/SMAD3. In addition, TGFβR1 can activate ‘non-canonical’ 
signaling pathways, most commonly p38 MAP kinase (p38), MAPK/ERK Kinase-1&-2 
(MEK1/2), and c-Jun N-terminal kinase (JNK) (39). To evaluate how TGF-β induces β3, 
tumor cells were treated with TGF-β in combination with pharmacological inhibitors for 
p38, MEK1/2, JNK, or TGFβRI kinase activity at the site specific for SMAD2/SMAD3 
phosphorylation (see Fig. 4 for details). In both PyMT-Bo1 and 4T1, only pharmacological 
inhibition of SMAD2/SMAD3 phosphorylation completely ablated β3 upregulation. This 
was observed by flow cytometry for surface β3 expression (Fig. 4A,B) and qPCR analysis 
for β3 mRNA levels (Supplemental Fig. S3A). Western blot analysis confirmed selective 
inhibition of SMAD2/SMAD3 phosphorylation (Fig. 4C) and suppression of total β3 protein 
(Fig. 4D) with TGFβRI kinase inhibition. To determine whether TGF-β signaling was 
responsible for tumoral β3 induction in vivo, mice bearing human MDA-MB-231 triple-
negative breast cancer bone metastases were treated daily with a pharmacological TGFβRI 
kinase inhibitor. TGFβRI kinase inhibition significantly suppressed β3 expression on MDA-
MB-231 breast cancer bone metastases (Fig. 4E), demonstrating the role of TGF-β signaling 
in β3 induction on breast cancer cells within the bone microenvironment. TGFβRI kinase 
inhibition resulted in an approximately 1.6-fold reduction in MDA-MB-231 bone metastatic 
tumor burden (Supplemental Fig. S3B), consistent with a previous report (30).
Integrin αvβ3-targeted micelle nanoparticles colocalize with breast cancer bone 
metastases
To evaluate whether bone metastatic induction of β3 could be therapeutically exploited, we 
sought to examine the potential of nanotherapy targeting integrin αvβ3. We used single-lipid 
phospholipid/polysorbate-80 micelle nanoparticles (MPs, ~12.5 nm), coated with a well-
characterized quinolone nonpeptide targeting ligand with enhanced specificity for activated 
αvβ3 (Supplemental Fig. S4A). The specificity of this targeting ligand for integrin αvβ3 has 
been demonstrated through a variety of assays both in vitro and in vivo (32-36) (see 
Materials and Methods for details). To test the effectiveness of integrin αvβ3 as a target for 
enhancing drug delivery to bone metastases, rhodamine-labeled αvβ3-targeted MPs (αvβ3-
MPs) or non-targeted MPs were administered intravenously into mice bearing PyMT-Bo1 
bone metastases. Immunofluorescent analysis of bone metastases revealed strong 
colocalization of αvβ3-MPs with bone metastases, while non-targeted MPs displayed only 
minor colocalization (Fig. 5A). Furthermore, accumulation of either αvβ3-MPs or MPs 
within tumor-free bone marrow was negligible (Supplemental Fig. S4B). Together, these 
results demonstrate the targeting potential and specificity of αvβ3-MPs for bone metastases.
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Next, we sought to evaluate the therapeutic efficacy of αvβ3-MP-mediated drug delivery. 
Nanotherapeutics often suffer from a premature loss of drug payloads during circulation and 
diminished intracellular drug bioavailability due to endosomal entrapment (40). To 
overcome these problems, a lipase-labile phospholipid-prodrug concept was employed, in 
which drug cargo is coupled to the Sn2 acyl-chain of phosphatidylcholine. This 
phospholipid-prodrug can be stably incorporated into the MP membrane during self-
assembly and provides drug retention during circulation (35). Upon αvβ3-MP binding to 
activated αvβ3 on target cells, a hemifusion complex forms between MPs and the plasma 
membrane, enabling endocytosis-independent “contact-facilitated drug delivery” (see Fig. 
5B for details) (36,41).
The chemotherapeutic agent selected for nanoparticle-delivery was docetaxel (DTX), a 
potent microtubule inhibitor employed as a first-line agent against breast cancer (42). We 
modified DTX as an Sn2 lipase-labile phospholipid-prodrug (DTX-PD) to enable αvβ3-MP 
delivery (Fig. 5B) (32). In vitro, PyMT-Bo1 cells were markedly sensitive to both DTX and 
DTX-PD, with a bioequivalent IC50 of 5.5 nM (Fig. 5C). Unfortunately, chemotherapeutics 
such as DTX rarely eradicate bone metastases in human patients (3,4) and can induce off-
target toxicity such as hair loss, neuropathy, pancytopenia, and liver toxicity (42). To test the 
efficacy of DTX against PyMT-Bo1 cells in vivo, mice were intracardiac injected with 
PyMT-Bo1 cells. BLI analysis confirmed equivalent establishment of bone metastases on 
day 3 post-intracardiac injection, and mice bearing PyMT-Bo1 metastases received 
intravenous DTX treatments beginning on day 4 post-intracardiac injection (see Fig. 5D). 
Animals experienced dose-dependent DTX-induced hematological toxicity (Supplemental 
Fig. S5A), yet metastatic tumor burden in the liver, kidney, or bone was not attenuated by 
DTX treatment, and lung metastatic tumor burden was only significantly reduced at the 
highest DTX dose of 20 mg/kg/week (Fig. 5E). Thus, while DTX was potently suppressive 
against PyMT-Bo1 in vitro, DTX displayed limited efficacy against PyMT-Bo1 metastases in 
vivo.
αvβ3-MP-mediated drug delivery of docetaxel attenuates bone metastases
To evaluate the therapeutic potential of αvβ3-targeted delivery of DTX-PD against PyMT-
Bo1 bone metastases, mice were treated with DTX, or an equimolar amount of DTX-PD 
encapsulated by αvβ3-MP (αvβ3-MP/DTX-PD). In parallel, two control nanoparticle 
treatments were evaluated to assess the in vivo specificity of αvβ3-MP targeting, and the 
specificity of docetaxel-mediated tumor-suppressive effects: non-targeted MP/DTX-PD and 
cargo-free αvβ3-MP without DTX-PD cargo, respectively.
As before, BLI analysis on day 3 post-intracardiac injection confirmed PyMT-Bo1 bone 
metastatic establishment and treatment began on day 4, with a cumulative dose of 5.55 
mg/kg DTX or equimolar dose of MP-encapsulated DTX-PD (see Fig. 5D). On day 12, ex 
vivo BLI analysis of bone metastases revealed that αvβ3-MP/DTX-PD significantly 
attenuated bone metastatic tumor burden, while no significant attenuation was observed with 
DTX treatment (Fig. 6A,B). Consistent with this result, histological analysis of bone tumor 
burden (Fig. 6C) and x-ray analysis of tumor-associated bone loss (Fig. 6D) revealed a 
significant reduction with αvβ3-MP/DTX-PD treatment as compared to saline, and no 
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significant attenuation with DTX. BLI analysis of visceral metastases within the liver, lungs, 
kidneys, and brain revealed that neither αvβ3-MP/DTX-PD nor DTX resulted in significant 
attenuation (Supplemental Fig. S5B), supporting our previous observations concerning bone-
specific β3 expression and resistance of PyMT-Bo1 metastases to DTX.
Hepatotoxicity was tested by serum liver function tests for aspartate transaminase (AST) and 
alanine transaminase (ALT). DTX treatment resulted in elevated levels of AST and ALT 
outside of the normal ranges, while αvβ3-MP/DTX-PD treatment displayed no evidence of 
hepatotoxicity (Fig. 6E). Both renal function, assessed by blood urea nitrogen (BUN), and 
whole blood counts were within the normal range among mice treated with saline, DTX, or 
αvβ3-MP/DTX-PD (Fig. 6E and Supplemental Fig. S5C).
Neither non-targeted MP/DTX-PD nor cargo-free αvβ3-MP treatment significantly altered 
bone metastatic tumor burden or bone destruction, demonstrating the necessity of αvβ3-MP 
targeting and the specificity of docetaxel in mediating the tumor-suppressive effects of this 
nanotherapy (Supplemental Fig. S6A-D). Control αvβ3-MP treated mice displayed elevated 
levels of AST, but ALT, renal, and hematological toxicities were within the normal range for 
αvβ3-MP and non-targeted MP/DTX-PD treatments (Supplemental Fig. S6E,F).
To evaluate the potential mechanism of αvβ3-MP/DTX-PD anti-bone metastatic activity, we 
quantified osteoclast number at the tumor-bone interface, which was unchanged between 
saline, DTX, and αvβ3-MP/DTX-PD treatments (Fig. 6F), demonstrating that αvβ3-MP/
DTX-PD attenuates tumor-induced bone loss independent of inhibition of osteoclast 
formation or osteoclast killing. To assess whether tumor cells responded to the effects of the 
chemotherapy, we measured tumor proliferation by immunohistochemistry for proliferating 
cell nuclear antigen (PCNA). Bone metastatic tumor cells treated with αvβ3-MP/DTX-PD 
displayed a significantly lower proliferation index than saline or DTX (Fig. 6G). 
Collectively, this work provides support for safer, more effective drug delivery against breast 
cancer bone metastases through exploitation of αvβ3 expression.
Discussion
Breast cancer bone metastases often irreversibly damage the skeleton, severely impacting 
quality of life and overall survival (2). Treating bone metastases has proven difficult, in part 
due to the bone microenvironment’s status as a chemo-protective niche (7), and coupled with 
inefficient delivery of drug to tumor cells in bone (43). While drug or nanoparticle 
conjugation to hydroxyapatite-avid molecules like bisphosphonates have provided positive 
results against mouse models of bone metastases (13,14), they lack direct specificity for 
tumor cells (8,15). In this study, we provide new evidence for integrin β3 as a molecular 
target on breast cancer bone metastases in mice and humans, and demonstrate the potential 
for improving therapeutic efficacy against this metastatic site via αvβ3-targeted approaches.
We first investigated differences in the physiological expression of integrin β3 on breast 
cancer tumors growing in different organs, in search of a tumor target on cells within the 
bone microenvironment. We demonstrated that orthotopic injection of murine breast cancer 
cell lines into the MFP establishes primary tumors with weak β3 expression. Intracardiac 
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injection establishes metastases within the lung and kidney with similarly weak β3 
expression, but establishes bone metastases with significantly stronger β3 expression, 
observed by both immunohistochemistry and flow cytometry of tumoral surface expression. 
In contrast, integrin αv was strongly expressed on tumors at all evaluated sites. We 
employed the widely-published intracardiac injection model to establish experimental bone 
and visceral metastases in these experiments. While this model does not recapitulate all 
steps of the metastatic cascade, circulating tumor cells still need to extravasate from the 
vessels to establish within the bone and other organs.
We also evaluated β3 expression on 42 human bone metastatic tissue samples, as compared 
to matching primary breast cancer biopsies from the same patient. Across nearly all patients, 
tumor-associated β3 expression was significantly higher on bone metastases. Furthermore, 
we show for the first time that β3 is highly expressed on breast cancer bone metastases of all 
subtypes, including those with the worst overall survival that have proven difficult to target 
(44), supporting the translational potential of targeting β3 in bone metastatic breast cancer 
patients.
Based on previous studies demonstrating that ectopic overexpression of β3 enhances tumor 
cell establishment in bone (26,28), we considered the possibility that breast cancer bone 
metastases display elevated β3 due to preferential bone colonization of a tumor cell 
subpopulation with high basal β3 expression. We established bone metastases from FACS-
sorted tumor cell subpopulations, which were initially positive or negative for basal β3 
expression. Here, we demonstrated that initial β3 expression is dispensable for establishing 
breast cancer bone metastases with elevated β3 expression. This finding does not contradict 
the role of tumoral αvβ3 in enhancing bone colonization (26,28), as there are numerous 
ligands for αvβ3 within the bone microenvironment (17,18); rather, it indicates that tumoral 
β3 can be induced during the establishment of bone metastases, suggesting that β3 
expression might be regulated by the bone microenvironment itself.
The bone is a natural reservoir for TGF-β, which is stored in the matrix as an inactive latent 
complex that must be liberated for bioactivation (45). Bioactive TGF-β plays a critical role 
in both the homeostatic and pathologic bone microenvironment, regulating osteolytic 
destruction and pathologic muscle weakness (30,46). TGF-β has been shown to induce β3 
expression on normal and transformed mammary epithelial cells (47-49), but the 
physiological regulation of tumoral β3 in vivo has not been explored. Here, we demonstrated 
that TGF-β strongly induces tumoral β3, and analysis of other integrin subunits of interest 
revealed that TGF-β induces integrin β3 more strongly than any other. Furthermore, we 
determined that TGF-β induces β3 through TGFβRI phosphorylation of SMAD2/SMAD3, 
evaluated at the transcriptional, total protein, and cell surface expression level. And for the 
first time, we demonstrate that TGF-β signaling is required for integrin β3 induction by 
breast cancer cells within the bone.
We were surprised by the lack of tumoral β3 upregulation in the MFP tumor or visceral 
metastases, where TGF-β can be present. This observation suggests that other 
microenvironments either lack a sufficient amount of bioactive TGF-β necessary for tumoral 
β3 induction, or contain inhibitors of TGF-β or SMAD2/SMAD3 signaling that prevent 
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TGF-β-mediated induction of tumoral β3. Studies are in progress to define the molecular 
mechanism underlying the low expression of tumoral β3 outside of the bone.
Selective elevation of β3 on bone metastases prompted us to explore αvβ3-targeted 
nanotherapy as a means to overcome the barriers limiting effective treatment. We selected 
phospholipid/polysorbate-80 micelle nanoparticles (MPs) for their small size (~12.5 nm) and 
unique mechanism of drug delivery (see Fig. 5B for details), which overcomes two problems 
that often hinder effective nanotherapy: poor intracellular drug bioavailability and premature 
loss of drug during circulation (40). Micelle nanoparticles deliver phospholipid-prodrug 
cargo directly to the target cell’s plasma membrane, where bioactive free-drug is 
enzymatically liberated directly into the cytoplasm by phospholipase activity (36,41). 
Furthermore, phospholipid-prodrug is stably incorporated into the MP-single lipid layer, 
thereby minimizing passive drug loss during circulation (35). Administering rhodamine-
labeled MPs or αvβ3-MPs into mice bearing breast cancer bone metastases resulted in 
stronger αvβ3-MP colocalization with bone metastases, compared to a 6.5-fold reduction in 
colocalization with non-targeted MPs. To examine the importance of MP’s small size in 
bone metastatic colocalization, we also evaluated the colocalization potential of significantly 
larger αvβ3-targeted perfluorocarbon nanoparticles (~250nm) (35). We observed that 
fluorescently-labeled αvβ3-targeted perfluorocarbon nanoparticles were much less effective 
at localizing to the center of bone metastases (data not shown). These observations prompted 
us to proceed with αvβ3-MP-mediated drug delivery, and we selected the chemotherapeutic 
docetaxel (DTX) as cargo for lipase-labile phospholipid-prodrug modification (DTX-PD).
While PyMT-Bo1 breast cancer cells are equally sensitive to both DTX and DTX-PD in 
vitro, PyMT-Bo1 metastases were strikingly resistant in vivo, with bone metastatic tumor 
burden essentially unaffected by DTX treatment even at the highest, most toxic dose tested 
(20 mg/kg/week). These observations highlight the difficulty of achieving an inhibitory dose 
of chemotherapy at metastatic sites in vivo. To test the efficacy of MP-encapsulated DTX-
PD, mice bearing PyMT-Bo1 metastases were treated with a suboptimal DTX dose 
(5.55mg/kg/week), 3.6-fold lower than the previously tested 20 mg/kg/week DTX dose 
which did not significantly attenuate bone metastases. At this suboptimal dose, we observed 
a significant attenuation of bone metastatic tumor burden and tumor-associated bone loss 
with αvβ3-MP/DTX-PD treatment, as compared to no significant attenuation by equimolar 
DTX treatment. Furthermore, neither cargo-free αvβ3-MP treatment nor non-targeted MP/
DTX-PD treatment significantly altered bone metastatic tumor burden or osteolytic bone 
destruction. The observation that micelle coating with the αvβ3-targeting ligand was 
necessary for bone metastatic colocalization, coupled with fact that αvβ3-MP/DTX-PD 
failed to attenuate metastases outside of β3-expressing bone metastases, provides additional 
support for the in vivo specificity of the αvβ3-targeting ligand for integrin αvβ3, in line 
with previous reports (32-36).
To examine the potential mechanism of αvβ3-MP-mediated activity, we quantified 
osteoclast number at the tumor/bone interface, which is reflective of osteoclast formation 
and serves as a useful indicator of bone resorption. Previous studies have found that 
osteoclast formation is markedly sensitive to inhibition by DTX, even at nanomolar 
concentrations (50). Osteoclast number at the tumor/bone interface was similar between 
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αvβ3-MP/DTX-PD and saline treatment groups, demonstrating that αvβ3-MP/DTX-PD 
treatment attenuates bone metastases and tumor-associated bone loss independent of 
inhibiting osteoclast formation or direct osteoclast killing. It is possible that there remains an 
effect of αvβ3-MP/DTX-PD treatment on osteoclast function that was not revealed by 
histomorphometric analyses.
We evaluated tumor cell proliferation through expression quantification of proliferating cell 
nuclear antigen (PCNA), a DNA polymerase processivity factor required for DNA synthesis 
during replication. DTX inhibits tumor proliferation through effects on microtubule 
stabilization and disruption of mitotic spindle assembly (42). We found that αvβ3-MP/DTX-
PD treatment significantly decreased PCNA expression on bone-residing tumor cells, as 
compared to saline and DTX treatment. Taken together with the osteoclast 
histomorphometry result, these observations suggest that αvβ3-MP/DTX-PD attenuated 
bone metastases due to enhanced therapeutic efficacy against bone-residing tumor cells.
We observed that DTX administration resulted in increased hepatotoxicity, while 
hematological values and liver function tests remained within normal limits following αvβ3-
MP/DTX-PD treatment. This work thus provides support for safer, more effective drug 
delivery against bone metastases through exploitation of αvβ3 expression on breast cancer 
cells within bone. Going forward, αvβ3-targeted drug cargo could be modified to fit specific 
treatment needs.
We recognize the limitation of αvβ3-targeted nanotherapy against breast cancer metastases 
outside of the bone. Nevertheless, bone metastases occur in approximately 70% of 
metastatic breast cancer patients and represent the only metastatic site in approximately 30% 
of patients, suggesting that a substantial number of patients could benefit from this approach 
(1,44). Collectively, we provide support for integrin αvβ3-targeted drug delivery as a bone-
specific therapeutic strategy to address the unmet clinical need for effective treatments 
against breast cancer bone metastases.
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Figure 1. 
Integrin β3 is preferential induced on breast cancer cells within the bone microenvironment. 
(A) Immunohistochemistry for β3 on PyMT-Bo1 mammary tumors or metastases, 
established by orthotopic or intracardiac injection into separate cohorts of mice, respectively. 
Tumors were removed 12 days post-injection. Representative images (left), quantification of 
DAB-stained tumors (right), n=4 per group. Scale=50 μm. One-way ANOVA with Tukey’s 
post-hoc test, **** P<0.0001. (B,C) Mammary tumors or bone metastases were established 
as previously described. Isolated tumor cells were identified based on cytokeratin 18 
expression (CK18+) and evaluated by flow cytometry for surface β3 expression. 
Representative samples (left). (B) PyMT-Bo1 cells, 13 days post-injection, n=3 mammary, 
n=4 bone. (C) 4T1 cells, 15 days post-injection, n=5 mammary, n=4 bone. Two-tailed 
unpaired t-test, *** P<0.001, ** P<0.01. Data presented as mean±SEM.
Ross et al. Page 21
Cancer Res. Author manuscript; available in PMC 2018 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Immunohistochemistry for β3 on patient-matched primary breast cancer and bone metastatic 
biopsies. (A) Semi-quantitatively analysis of the extent and intensity of tumor-associated β3 
expression, using the histoscore (H-score) system, n=42 matched-pairs, two-tailed Wilcoxon 
signed-rank test, **** P<0.0001. (B) Subdivision of Fig. 2A by molecular subtype (see 
Materials and Methods for details). Representative images of patient-matched primary 
tumors and bone metastases (right). Scale=50 μm. Two-tailed paired t-test, **** P<0.0001, 
*** P<0.001, ** P<0.01, * P<0.05. Data presented as mean±SEM.
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Figure 3. 
Bone microenvironment and TGF-β stimulation induce tumoral β3. (A) In vitro PyMT-Bo1 
cells were FACS sorted into three groups based on basal β3 expression: β3-, β3+, and 
control β3-all. Immediately after collection, cells were intracardiac injected into separate 
groups of mice. (B) 13 days post-injection, isolated bone metastatic PyMT-Bo1 cells were 
identified by CK18+ and evaluated by flow cytometry for surface β3 expression. 
Representative samples (left), n=4 β3-, n=4 β3-all, n=5 β3+ (right). One-way ANOVA with 
Tukey’s post-hoc test, ns=(not significant). (C,D) qPCR analysis of β3 (Itgb3) mRNA 
expression by PyMT-Bo1 or 4T1 cells cultured in vitro, following 24 hours stimulation with 
the listed factors (see Materials and Methods for details). One of two biological replicates, 
each in technical duplicate. One-way ANOVA with Tukey’s post-hoc test, **** P<0.0001. 
Data presented as mean±SEM.
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Figure 4. 
TGF-β induces tumoral β3 through TGFβRI-mediated phosphorylation of SMAD2/
SMAD3. (A,B) In vitro tumor cells treated with either 2 ng/mL TGF-β1 or DMSO control, 
in the presence of a pharmacological inhibitor: SMAD2/3i (20μM SB431542), MEK1/2i (20 
μM U0126), p38i (20μM SB203580), or JNKi (50μM SP600125). After 48 hours, flow 
cytometry for surface β3 expression was evaluated on (A) PyMT-Bo1 cells, or (B) 4T1 cells. 
Representative experiment (left), n=3 biological replicates (right). One-way ANOVA with 
Tukey’s post-hoc test, with denoted significance in relation to DMSO control, **** 
P<0.0001, *** P<0.001, * P<0.05. (C,D) Western blot analysis of in vitro PyMT-Bo1 cells 
treated as previously described, for (C) 3 hours, or (D) 24 hours. (E) Mice intracardiac 
injected with MDA-MB-231 cells were treated daily with a TGFβRI kinase inhibitor of 
SMAD2/3 phosphorylation (SD-208, 60 mg/kg/d) or vehicle control (1% methylcellulose) 
for 28 days. Immunohistochemistry for β3 with representative images (left) and 
quantification of DAB-stained bone metastases, n=4 (right). Scale=100 μm. Two-tailed 
unpaired t-test, *** P<0.001. Data presented as mean±SEM.
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Figure 5. 
Micelle nanoparticles targeting integrin αvβ3 colocalize with breast cancer bone metastases 
and are designed to carry the chemotherapeutic docetaxel. (A) Mice bearing PyMT-Bo1 
bone metastases were intravenously injected with rhodamine-labeled (red) non-targeted MPs 
or αvβ3-MPs. After 3 hours, bones were removed and fresh-frozen sections were 
immunofluorescently imaged. DAPI nuclear counterstain (blue). Representative images 
(left), quantification of fluorescent colocalization with the bone metastases, n=3 per group 
(right). Scale=200 μm. Two-tailed unpaired t-test, *** P<0.001. (B) Schematic of αvβ3-MP-
mediated “contact-facilitated drug delivery.” Upon hemifusion, phospholipid-conjugated 
docetaxel-prodrug (DTX-PD) transfers to the target cell’s plasma membrane, where 
bioactive DTX is enzymatically liberated by phospholipases and released directly into the 
cytoplasm. (C) In vitro PyMT-Bo1 cell viability via MTT assay after 72 hours of DTX or 
DTX-PD treatment. n=2 biological replicates, each in technical triplicate. (D) Treatment 
schematic of mice intracardiac injected with PyMT-Bo1 cells. Representative ex vivo BLI of 
tumor-bearing organs on day 12. (E) Following the schematic in Fig. 5D, mice were treated 
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with increasing concentrations of docetaxel, with the cumulative dose as indicated. Day 12 
ex vivo PyMT-Bo1 metastatic tumor burden by BLI analysis, n=6. Bone, Kidney, Lung: two-
tailed unpaired t-test. Liver: two-tailed Mann–Whitney U-test. All with Bonferroni 
correction for a priori multiple comparisons between control 0 mg/kg and each DTX 
treatment group, ** P<(0.01/4), * P<(0.05/4), ns=(not significant). Data presented as mean
±SEM.
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Figure 6. 
Integrin αvβ3-targeted nanotherapy attenuates breast cancer bone metastases. Following the 
schematic described in Fig. 5D, mice were treated with either a cumulative dose of 5.55 
mg/kg docetaxel (DTX), an equimolar dose of docetaxel-prodrug encapsulated by αvβ3-MP 
(αvβ3-MP/DTX-PD), or saline. Analyses completed on samples collected on day 12 post-
injection. (A) Representative in vivo BLI of mice bearing PyMT-Bo1 bone metastases, 
matching day 3 and day 12 post-injected mice from each group (B) Ex vivo PyMT-Bo1 bone 
metastatic tumor burden by BLI analysis, n=9. (C) Histological analysis of tumor burden 
within the tibiofemoral joint, n=4. (D) X-ray analysis of osteolytic bone destruction, n=9. 
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(B-D) Scale=1 mm, two-tailed unpaired t-test with Bonferroni correction for a priori 
multiple comparisons between saline and each experimental treatment, * P<(0.05/2). (E) 
Serum chemistry analysis of BUN, AST, and ALT, n=5. Gray range illustrates the normal 
reference range (mean±2*SD) for female C57BL/6 mice bearing PyMT-Bo1 metastases. (F) 
TRAP staining for quantification of osteoclast number per millimeter of bone surface 
(N.OC/mmB.S.) at the tumor (T), bone (B) interface, n=4. (G) Quantification of PCNA-
positive cells within the bone metastatic region, n=3. (F-G) Scale=50 μm, one-way ANOVA 
with Tukey’s post-hoc test, ** P<0.01, * P<0.05, ns=(not significant). All images are 
representative and data presented as mean±SEM.
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